IRIS
ESPOSITO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.425
AS - Asia 2.663
EU - Europa 2.408
SA - Sud America 331
AF - Africa 43
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.876
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.321
SG - Singapore 1.297
RU - Federazione Russa 780
IE - Irlanda 698
CN - Cina 529
HK - Hong Kong 312
BR - Brasile 277
VN - Vietnam 257
DE - Germania 167
UA - Ucraina 157
IT - Italia 154
FR - Francia 121
FI - Finlandia 97
BD - Bangladesh 88
GB - Regno Unito 68
SE - Svezia 58
CA - Canada 51
IN - India 42
TR - Turchia 31
MX - Messico 30
JP - Giappone 24
AR - Argentina 18
NL - Olanda 17
BE - Belgio 16
PL - Polonia 15
IQ - Iraq 14
ZA - Sudafrica 13
ES - Italia 12
ID - Indonesia 12
LT - Lituania 12
CO - Colombia 11
AT - Austria 9
CZ - Repubblica Ceca 8
VE - Venezuela 7
PH - Filippine 6
PK - Pakistan 6
SA - Arabia Saudita 6
MA - Marocco 5
NP - Nepal 5
PE - Perù 5
TN - Tunisia 5
DZ - Algeria 4
HN - Honduras 4
JM - Giamaica 4
KR - Corea 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
CR - Costa Rica 3
EC - Ecuador 3
HU - Ungheria 3
MY - Malesia 3
TH - Thailandia 3
TW - Taiwan 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
EG - Egitto 2
GA - Gabon 2
GT - Guatemala 2
IL - Israele 2
JO - Giordania 2
KE - Kenya 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
GP - Guadalupe 1
GR - Grecia 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
Totale 10.872
Salva come PNG Salva come JPEG
Città #
Dallas 718
Singapore 713
Dublin 696
San Jose 641
Jacksonville 613
Chandler 469
Ashburn 366
Hong Kong 306
Council Bluffs 296
Santa Clara 289
The Dalles 202
Boardman 156
Moscow 154
New York 136
Beijing 113
Lawrence 102
Princeton 102
Ho Chi Minh City 75
Nanjing 75
Los Angeles 73
Ann Arbor 71
Wilmington 66
Hanoi 64
Lappeenranta 56
Dearborn 55
Lauterbourg 47
Munich 39
Orem 32
São Paulo 31
Columbus 28
Rome 25
Shenyang 24
Helsinki 22
Nanchang 22
Tokyo 21
Jinan 18
Brooklyn 17
Hebei 17
London 17
Frankfurt am Main 16
Jiaxing 16
San Francisco 16
Brussels 15
Denver 15
Hefei 15
Chennai 14
Chicago 14
Houston 14
Montreal 14
Turku 14
Des Moines 13
Manchester 13
Warsaw 13
Da Nang 12
Haiphong 12
Izmir 12
San Mateo 12
Amsterdam 11
Atlanta 11
Boston 11
Changsha 10
Mexico City 10
Milan 10
Stockholm 10
Toronto 10
Nuremberg 9
Phoenix 9
Assago 8
Brno 8
Curitiba 8
Mumbai 8
Norwalk 8
Seattle 8
Woodbridge 8
Buffalo 7
Falkenstein 7
Jakarta 7
Johannesburg 7
Kunming 7
Ningbo 7
Paris 7
Tianjin 7
Baghdad 6
Biên Hòa 6
Brasília 6
Mountain View 6
Zhengzhou 6
Bogotá 5
Dhaka 5
Dong Ket 5
Florence 5
Guangzhou 5
New Delhi 5
Pune 5
Ankara 4
Bắc Ninh 4
Campinas 4
Can Tho 4
Cebu City 4
Charlotte 4
Totale 7.519
Salva come PNG Salva come JPEG
Nome #
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 136
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 133
Exploring the interplay of atopic dermatitis severity with sleep and mental health: a case-control study in adult patients 132
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 130
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 117
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 116
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 113
Management of Cutaneous Squamous Cell Carcinoma of the Scalp in Kidney Transplant Recipients 112
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 112
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 111
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 111
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 110
Impact of COVID-19 Pandemic on Delay of Melanoma Diagnosis: A Systematic Review and Meta-Analysis 109
AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History 106
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 103
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 100
Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum 96
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study 96
Muir-Torre syndrome with fatal outcome 96
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 96
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 94
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 92
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 92
Dermatiti da Piogeni o Piodermiti 90
Systemic treatment: Ciclosporin 90
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 90
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 88
Histopathology of the skin in rheumatic diseases 88
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 88
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 87
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 87
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 86
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 85
Treatment of erytrodermic psoriasis with etanercept 84
Treatment of erythrodermic psoriasis with etanercept 84
An Italian study on psoriasis and depression 84
Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review 82
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 82
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 82
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 82
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 82
Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations 81
Treatment of early stage mycosis fungoides with topical bexarotene 81
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 81
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 81
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 81
Quality of life 80
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 80
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 80
Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic 80
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 79
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years 79
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 79
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 79
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 79
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 79
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. 78
Psoriasis target therapy: ustekinumab 78
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 78
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 78
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 77
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 77
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 77
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis 76
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 76
Clinical Variants 75
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 75
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 75
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 75
UVA1 Laser in the Treatment of Vitiligo 74
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 74
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 74
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 74
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 74
Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi 73
PsoBioVax: A multicentric Italian case–control study of the immunological response to anti-SARS-CoV-2 vaccine among psoriatic patients under biological therapy 73
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 72
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 72
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 72
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 72
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 72
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 71
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 70
Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1 70
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 70
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 70
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 70
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 70
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 70
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 69
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 69
Dermatiti da piogeni o piodermiti 68
UVB 308 nm XeCl excimer laser for mycosis fungoides 68
Differences in percutaneous absorption in normal and atopic dermatitis skin in relation to molecular weigh. 67
Long-term efficacy of etanercept in hidradenitis suppurativa. 67
Long-lasting remission of pemphigus vulgaris treated with rituximab 67
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 67
The Combination of Dupilumab with Other Monoclonal Antibodies. 66
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study 66
Topical corticotherapy: the expert's opinion 65
Totale 8.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 0 0 13
2021/2022334 7 4 19 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024321 59 25 35 27 25 88 4 7 0 22 6 23
2024/20252.106 52 30 171 66 308 163 329 106 520 61 133 167
2025/20265.222 213 357 512 437 367 252 1.022 354 507 659 444 98
Totale 11.082